Once Weekly Mazdutide effectvely reduced body weight in obese individuals: NEJM

A new study published in The New England Journal of Medicine showed that once weekly mazdutide at a dosage of 4 mg or 6 mg for 32 weeks resulted in clinically significant weight loss in Chinese adults who were overweight or obese.

This research randomly assigned adults aged 18 to 75 with a body-mass index (BMI) of at least 28 or 24 to less than 28 plus at least one weight-related coexisting condition to receive 4 mg of mazdutide, 6 mg of mazdutide, or placebo for 48 weeks in China.

According to a treatment-policy estimand analysis, which evaluated effects independent of early mazdutide or placebo discontinuation and the start of new anti-obesity therapies, the two main endpoints were the percentage change in body weight from baseline and a weight loss of at least 5% at week 32.

At baseline, the mean BMI was 31.1 and the mean body weight was 87.2 kg among 610 individuals. The 4-mg mazdutide group experienced a mean percentage change in body weight from baseline of –10.09% (95% CI), −11.15 to −9.04; the 6-mg mazdutide group experienced a mean percentage change of –12.55% (95% CI, −13.64 to −11.45); and the placebo group experienced a mean percentage change of 0.45% (95% CI, −0.61 to 1.52); 73.9%, 82.0%, and 10.5% of the participants, respectively, experienced a decrease in weight of at least 5%.

The 4-mg mazdutide group experienced a mean percentage change in body weight from baseline of -11.00% (95% CI, −12.27 to −9.73), the 6-mg mazdutide group experienced a mean percentage change of -14.01% (95% CI, −15.36 to −12.66), and the placebo group experienced a mean percentage change of 0.30% (95% CI, −0.98 to 1.58).

Of the participants, 35.7%, 49.5%, and 2.0%, respectively, experienced a weight reduction of at least 15%. Mazdutide showed positive results on all predetermined cardiometabolic measurements. Gastrointestinal side effects were the most commonly reported and were primarily mild to moderate in intensity.

The 4-mg mazdutide dose had a 1.5% incidence of adverse events that resulted in the trial regimen being discontinued, the 6-mg mazdutide dose had a 0.5% incidence, and the placebo had a 1.0% incidence. Overall, treatment with mazdutide at dosages of 4 mg and 6 mg resulted in clinically significant weight reductions at 32 weeks in this research, which included Chinese people who were obese or overweight.

Source:

Ji, L., Jiang, H., Bi, Y., Li, H., Tian, J., Liu, D., Zhao, Y., Qiu, W., Huang, C., Chen, L., Zhong, S., Han, J., Zhang, Y., Lian, Q., Yang, P., Lv, L., Gu, J., Liu, Z., Deng, H., … GLORY-1 Investigators. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2411528